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Recommendations for the scientific use of this probe: 
 
Loss of VHR phosphatase causes cell cycle arrest in HeLa carcinoma cells, suggesting that 
VHR inhibition may be a useful approach to halt the growth of cancer cells. VHR is also 
upregulated in several cervix cancer cell lines as well as in carcinomas of the uterine cervix. 
Here we report the development of multidentate small-molecule inhibitors of VHR that 
inhibit its enzymatic activity at nanomolar concentrations and are selective for VHR over 
HePTP and MKP-1.  
 
This novel chemical probe appears to interact with both the phosphate-binding pocket and 
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in probing these interactions and elucidating the molecular mechanism of selectivity against 
this phosphatase and the functional consequences for cancer biology.    
 
The probe decreased the proliferation of cervix cancer cells at low micromolar 
concentrations, while growth of primary normal keratinocytes was not affected.  Thus this 
probe may also be a starting point to develop drugs for the treatment of cervical cancer. 
 
1. Scientific Rationale for Project 
 
Specific aims 
The overall goal is to develop selective and efficient VHR inhibitors for basic research on 
signal transduction processes and MAP kinase regulation. For the future, this work could 
also create proof-of concept evidence that VHR is a good drug target for the treatment of 
cervical cancer. Some of these inhibitors may turn out to be suitable for further 
development towards clinical use. 
 
Background and Significance 
The Vaccinia H1-related (VHR) protein tyrosine phosphatase is a relatively small member of 
the subclass of dual-specificity phosphatases1 with only 185 amino acids (mw 21 kDa) and 
with no apparent targeting domain or docking site.2 Compared to the phospho-tyrosine 
(pTyr)- specific classical PTPs, the crystal structure of VHR revealed a much shallower active 
site, which allows VHR to act on both pTyr and phospho-threonine (pThr) in its substrates.3 
VHR dephosphorylates and thereby inactivates extracellular signal-regulated kinases Erk1/2 
and c-Jun N-terminal kinases Jnk1/2, but not p38.4-6 These mitogen-activated protein 
kinases (MAP kinases) mediate major signaling pathways triggered by extracellular growth 
factor, stress, or cytokines7 and regulate cellular processes such as differentiation, 
proliferation and apoptosis.8,9  Unlike many MKPs, VHR expression is not induced in 
response to activation of MAP kinases10 but is instead regulated during cell cycle 
progression.11  The loss of VHR causes cell cycle arrest in HeLa carcinoma cells, suggesting 
that VHR inhibition may be a useful approach to halt the growth of cancer cells without the 
detrimental effects on normal cells. The assay provider recently reported that VHR is 
upregulated in several cervical cancer cell lines as well as in squamous intraepithelial lesions 
and squamous cell carcinomas of the uterine cervix.12 
 
2. Project Description 
a. Describe the original goal for probe characteristics as identified in the 
CPDP.  
 
The ideal probe would be a new scaffold of improved potency (< 2-3 uM) over current 
probes in the literature and improved selectivity towards other phosphatases (at least 2-fold 
over either MKP-1 or HePTP). However, as there are very few potent phosphatase inhibitors 
and even fewer selective ones, any improvement in either potency or selectivity would be 
useful. Additionally activity in a cell based assay for direct substrates is a desired 
characteristic; however, if none of the scaffolds obtained by catalog or by medicinal 
chemistry efforts have cell activity, the probes will still be useful as in vitro biochemical 
tools. 
 
In the original CPDP, several compounds are disclosed as prior art, but none are more than 
potent than ~ 4 uM, reported as selective for VHR1 nor cell active without cellular toxicity 
and are reiterated below from H. Park et al. “Discovery of VHR Phosphatase Inhibitors with 
Micromolar Activity based on Structure-Based Virtual Screening” (2008) J Med Chem 3:877 
– 880 (the authors do not specify the stereochemistry as E or Z for these olefins. However, 
they do mention that the vendor is Interbioscreen).    
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There was no cell activity reported for compounds 1 – 6 in Figure 1, Table 1 (but they 
may have not been tested in cell assays).  Compounds 1 and 2 were purchased and 
provided to the assay provider for cell activity testing and reference. 
 
Table 1.  The inhibitory activities of compounds 1 -6 against VHRa   








1 82.8 3.7 2932059 34500079, 4450071 
2 83.5 4.7 1210330 51674707, 29248963, 
6159808 
3 77.2 13.9   
4 72.1 20.0   
5 74.1 24.2   
6 70.9 46.5   
aAt all concentrations of the inhibitors, the inhibition assay was performed in duplicates 
 
Additional VHR inhibitors (Table 2, Figure 2) were reported by Zhi et al. “Identification of a 
Potent Inhibitor of Human Dual-Specific 
Phosphatase, VHR, from Computer-Aided and 
NMR-Based Screening to Cellular Effects” (2007) 
ChemBioChem 8:2092-2099 GATPT is a stannous 
(tin containing compound and toxic) of no 
chemical interest or tractability. Has some 
reported cell activity, however it has been shown 
to be toxic. 
The following publications refer to these existing 
probes with PMIDs: 7556642, 11563920, 
11755399, 17933004, and 18236492. 
 
Table 2.  Inhibitory activities of compounds 
against VHRa   






GATPT 952 2.92 
AP1 673 56.95 
AP2 742 100.51 
AP3 632 45.84 
AP4 102b 26,200 
bCompound concentration was 10 mM 
Figure 1.  Chemical structures of prior art VHR inhibitors from Park et al. 2008 
Figure 2. Chemical structures of VHR 
inhibitors from Shi et al. 2007 
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b. For each assay implemented and screening run please provide: 
i. PubChem Bioassay Name(s), AID(s), Assay-Type (Primary, DR, 
Counterscreen, Secondary) 
ii. Assay Rationale & Description (when describing primary screen 
it would be useful to see standard metrics like, Z’, S:B for the 
optimized assay).  
The Vaccinia H1-related (VHR) PTP is a dual-specific Erk and Jnk phosphatase. This primary 
screen (AID1992) is based on a biochemical assay that employs a colorimetric readout 
based on the enzyme's ability to liberate phosphate from para-nitrophenyl phosphate 
(pNPP) and the reaction or the released phosphate with Biomol Green reagent.13  Following 
initial screening the hits are confirmed for activity using the same assay but from re-ordered 
stock solutions in duplicate single concentrations (AID1992), and then to determine the 
potency from full dose response curves (AID2004).  
 
Table of reagents and source. 
Assay materials: 
Table 4. Reagents used for the HTS experiments 
Reagents Supplier/Vendor 
Recombinant VHR (expressed & purified as per ref. 14) Dr. Tautz’s Lab 
p-Nitrophenyl phosphate (pNPP) Sigma (St. Louis, MO) 
BIOMOL GREEN BIOMOL Research Laboratories, Inc. 
(Plymouth Meeting, PA) 
Bis-Tris pH 6.0 reaction buffer  Sigma (St. Louis, MO) 
Dithiothreitol (DTT)  Sigma (St. Louis, MO) 
VHR  materials: 
1) Recombinant VHR was provided by Prof. Lutz Tautz (Burnham Institute for Medical 
Research, San Diego, CA) 
2) Assay buffer: 0.1 M Bis-Tris pH 6.0 with 1 mM dithiothreitol (DTT) 
3) 4 mM pNPP 
4) BIOMOL Green 2:1 addition to quench a 70 uL reaction volume  
 
VHR protocol: 
Each reaction contained 180 nM VHR, 4 mM pNPP, and 0.02 mg/mL compound in 0.1 M Bis-
Tris pH 6.0 reaction buffer with 1 mM dithiothreitol (DTT) present. The final volume 
amounted to 70 μL and contained 1.4% DMSO. The reaction was initiated by addition of 
pNPP after a preincubation of the enzyme with compounds for 10 min at room temperature. 
After 15 min, the reaction was quenched by addition of 140 μL BIOMOL GREEN reagent, and 
the pNPP hydrolysis was determined by measuring the absorbance of the complexed free 
phosphate at 620 nm. The nonenzymatic hydrolysis of the substrate was corrected by 
measuring the negative control without addition of enzyme. Other controls included a 
positive control (no inhibitor added), a background control (no substrate added), and a 
control with 200 uM of the general PTP inhibitor sodium orthovanadate. To quantitate the 
inhibitory efficacy of the library compounds, we determined the ratio of inhibition in 
Table 3. PubChem Assay Summaries for Probe project 
PubChem BioAssay Name AIDs Probe 
Type 





VHR1 Inhibitors – Primary  1992 Inhibitor Primary Biochemical Absorbance 
96-well 
VHR1 – Confirmatory (CP & DR) 1992, 
2004 
Inhibitor Confirmatory Biochemical Absorbance 
96-well 
VHR1 Inhibition – SAR support 2074 Inhibitor Secondary Biochemical Fluorescence 
96-well 
HePTP Inhibition - SAR 2082 Inhibitor Counterscreen Biochemical Fluorescence 
96-well 
MKP-1 Inhibition– SAR 2083 Inhibitor Counterscreen Biochemical Fluorescence 
96-wells 
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comparison to the positive control. Every compound with >60% inhibition was cherry-picked 
and rescreened to confirm it as a hit (AID1992) and confirmed for initial potency (AID2004). 
 
Rationale for confirmatory, counter and selectivity assays: 
VHR SAR assay: A higher sensitivity fluorogenic assay was developed and performed to 
study the structure-activity relationship on analogs of the confirmed  VHR hits reported in 
AID 2004. This VHR biochemical assay (AID2074) employs a fluorescent readout based on 
the enzyme's ability to catalyze the hydrolysis of 6,8-difluoro-4-methylumbelliferyl 
phosphate (DiFMUP) in the presence of an inhibitor.  
Counterassay (MKP-1): MAP kinase phosphatase 1 (MKP-1) is, like VHR, a dual-specific 
phosphatase and structurally closely related to VHR. MKP-1 also shares a physiological 
substrate with VHR, namely the extracellular signal-regulated kinases Erk1/2. Therefore, 
MKP-1 was chosen to assess the selectivity of the VHR1 inhibitors reported in AID 2004. 
This biochemical assay for MKP-1 (AID2083) employs the same fluorescent readout as the 
VHR SAR assay. 
Selectivity Assay (HePTP): In contrast, the hematopoietic tyrosine phosphatase (HePTP) 
is a classical pTyr-specific phosphatase. HePTP shares a physiological substrate with VHR, 
namely the extracellular signal-regulated kinases Erk1/2, and therefore was chosen to 
assess the selectivity of the VHR1 inhibitors reported in AID 2004. This biochemical assay 
for HePTP (AID2082) also employs the same fluorescent readout as the VHR SAR assay.  
The commonality of the assay format and readout ensure comparability of potency values in 
these three assays. 
General assay protocol: The PTP-catalyzed hydrolysis of 6,8-difluoro-4-methylumbelliferyl 
phosphate (DiFMUP) in the presence of compound was assayed at 30°C in a 60 uL 96-well 
format reaction system in 150 mM Bis-Tris, pH 6.0, assay buffer having an ionic strength of 
150 mM (adjusted with NaCl) and containing 1 mM DTT and 5%DMSO. At various 
concentrations of the compound, the initial rate at fixed DiFMUP concentration (equal to the 
corresponding Km value for each PTP) was determined using a FLx800 microplate reader 
(Bio-Tek Instruments, Inc.), an excitation wavelength of 360 nm, and measuring the 
emission of the fluorescent reaction product 6,8-difluoro-7-hydroxy-4-methylcoumarin 
(DiFMU) at 460 nm. The nonenzymatic hydrolysis of the substrate was corrected by 
measuring the control without addition of enzyme. The IC50 value was determined by 
plotting the relative activity versus inhibitor concentration and fitting to eq 1 using the 
software GraphPad Prism (GraphPad Software, Inc.).  
 
Vi/V0 = IC50/(IC50+ [I])  (eq. 1) 
 
In this case, Vi is the reaction velocity when the inhibitor concentration is [I], V0 is the 
reaction velocity with no inhibitor, and IC50=Ki + Ki[S]/Km. 
 
iii. Center Summary of Results 
We have completed the primary screen of 291,018 compounds from the MLSMR library 
(AID1654) using a colorimetric assay that measures the enzyme’s ability to liberate 
phosphate from para-nitrophenyl phosphate (PNPP) and detection of the released phosphate 
with Biomol Green reagent. However, at this juncture no VHR compounds of <2-3 uM 
potency with selectivity against other phosphatases (e.g. HePTP)  were found. This probe 
report describes the results of a parallel screen of the 49,840 drug-like molecules of the 
DIVERSet library from ChemBridge, Inc. (San Diego, CA), at the concentration of 0.02 
mg/mL in a 96-well format using an in vitro colorimetric phosphatase assay, in collaboration 
with the assay provider. The average Z’ for this assay was 0.85, the signal to background 
ratio was 3.8, the signal to noise ratio was 46.6 and the signal window was 34.7.  We found 
that 221 compounds inhibited VHR’s enzymatic activity to >60% (average of n=2) 
compared to a no-inhibitor control. For further evaluation, a total of 56 compounds were 
picked that inhibited VHR>90% (average of n=2). Michaelis-Menten kinetic studies revealed 
21 hits that inhibited the enzyme with Ki values <20 uM (Table 5). Clustering the 21 
compounds by a Tanimoto distance15 of 0.5 resulted in 12 different clusters and singletons, 
respectively, indicating a quite diverse chemical space covered by these molecules. The 
 
BCCG_VHR_Inhibitor_CID6161281_ver4 Page 6 of 15 Submitted 1Sep2010 Template H 
most active hit, 2-((Z)-4-oxo-5-((E)-3-phenylallylidene)-2-thioxothiazolidin-3-yl)ethane-
sulfonic acid, SID17460170 (1), inhibited VHR with a Ki value of 0.81 uM. In a counter 
screen against the protein tyrosine phosphatase, HePTP, only 1 and 1,4-
dimethoxyanthracene-9,10-dione, SID17438068 (8), and (1E,4E)-1-[5-(3,4-
dichlorophenyl)furan-2-yl]-5-(furan-2-yl)penta-1,4-dien-3-one, SID17461020 (18) were 
found to be selective for VHR (Figure 3).  
Table 5.  Most Potent VHR Screening Hits 
# PubChem SID Structure 
Ki 
(uM) 



























































Figure 3. Profiling of the 21 most active VHR screening hits at 20 uM against VHR (AID 2074) & HePTP (AID 
2082). Asterisks indicate compounds 1, 8, and 18 (Table 5), which appeared to be selectively inhibiting VHR 




Of these three compounds, only SID17460170 (1), showed a clear competitive inhibition 
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Lineweaver-Burk plots for SID17460170 (1) with VHR. (B) FlexX docking of SID17460170 (1) into 
the active site of VHR crystal structure (PDB code 1J4X).  The color code of the MOLCAD surface 
represents the lipophilic potential (brown: most hydrophobic, blue: most hydrophilic). 
 
c. Probe Optimization 
 
i. Describe SAR & chemistry strategy (including structure and 
data) that led to the probe. 
 
In Silico Docking.  To study the molecular basis for inhibition of VHR, we first used in silico 
docking to dock SID17460170 (1) and SID17438068 (8) into the active site of the VHR 
crystal structure (PDB code1J4X, ref 16). Compound SID17438068 (8) failed to dock into 
the catalytic pocket, further supporting an inhibition mechanism other than competitive. 
Because quinones like SID17438068 (8) are known to deactivate PTPs by oxidizing the 
catalytic cysteine residue,7 so we discarded SID17438068 (8) from further investigation. As 
for compound SID17460170 (1), the docking suggested that the sulfonic acid moiety 
functions as a phosphate mimic and binds into the catalytic pocket, forming a network of 
hydrogen bond interactions with the phosphate binding loop, also called P-loop (Figure 2B). 
In support of this, similar compounds lacking the sulfonic acid moiety did not inhibit VHR. 
Furthermore, the docking suggested that the oxo-thioxothiazolidine ring interacts with the 
rim of the catalytic pocket, whereas the diene linker and the phenyl ring make van der 
Waals interactions with a hydrophobic region, mainly formed by Leu25 and Tyr128 (Figure 
2B, above). 
 
SAR Analysis and Analogs of Lead Compound 1. By further analyzing the lipophilic 
potential of VHR’s active site surface area, we found a total of three distinct hydrophobic 
regions surrounding the catalytic pocket (Figure 2B). Compared to active site properties of 
solved PTP structures and homology models,17 this feature seems to be rather unique to 
VHR and, therefore, could be exploited for designing selective inhibitors. The exposed 
hydrophobic patches are formed by Leu25/Tyr128 and Leu16/Tyr23, which make up large 
portions of the substrate binding site,10 as well as by Phe68/ Met69, which is part of a loop 
opposite of the catalytic pocket (Figure 2B). In an attempt to find analogs of 1 that could 
target more than one of these hydrophobic regions, we kept the oxo-thioxothiazolidinyl-
ethanesulfonic acid moiety as hydrophilic pharmacophore, and subjected it to a substructure 
search among commercially available compounds.  The pharmacophore model and limited 













Six structures were identified that fulfilled the requirement of having additional multiple 
hydrophobic entities to interact with multiple hydrophobic regions in VHR’s active site. 
All compounds contained a 1-phenyl-substituted pyrazole ring, which at its 3-position linked 
to another, more variable entity (see Table 6). We obtained all six analogs and subjected 
them to direct measurements of VHR inhibition. Indeed, compounds CID-6161281, -
6274486, -5932584, -5998084, and -6166563 (SA1-5) showed excellent IC50 values of 18, 
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71, 74, 78, and 268 nM, respectively (Table 6). An aromatic group in position ‘R’, such as 
the benzoxy group in compounds CID-6161281, -6274486, -5932584, and -5998084 (SA1-
4), seemed to be very well accommodated by the protein, whereas sterically more 
demanding structures, such as the piperidinesulfonyl group in CID-6166563 (SA5) were 
less favorable. On the other hand, groups such as methyl in CID-6001181 (SA6) seemed to 
be too small to provide additional binding energy through van der Waals interactions. 
Interestingly, compounds CID-6161281, -6274486, -5932584, and -5998084 (SA1-4) only 
differ in their substituents at the benzoxy group. Chlorine in the para position was most 
favorable CID-6161281 (SA1), whereas substituents in the ortho-position, such as chlorine 
CID-6274486 (SA2) or fluorine CID-5932584 (SA3), had no effect on inhibitory activity 
against VHR in vitro. Testing the five best inhibitors CID-6161281, -6274486, -5932584, -
5998084, and -6166563 (SA1-5) against a panel of related PTPs demonstrated that they 
were at least 1 order of magnitude less potent for MKP-1 and HePTP (Table 6). MKP-1 and 
HePTP share the same physiological substrate with VHR, namely, the MAP kinase Erk, and 
MKP-1 is structurally closely related to VHR. 
 
Table 6.  In vitro potency and Selectivity of 1-phenylpyrazole VHR inhibitor analogs 









































85256227 6166563 0.27 2.8 2.4 
MLS-0425637 
(SA6) 
CH3 85256228 6001181 3.1 ND ND 
 
3.   Probe 
a. Chemical name of probe compound 
IUPAC:  2-[(5Z)-5-[[3-[4-[(4-chlorophenyl)methoxy]phenyl]-1-phenylpyrazol-4-
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b. Probe chemical structure including stereochemistry if known 
 
c. Structural verification information of probe SID 
Probe SID number is SID 85256223  Purity: >95% (HPLC-MS) 














HPLC 240 nM 
 




d. PubChem CID (corresponding to the SID) 
    PubChem CID is 6161281 (corresponding to SID 85256223) 
 
e. If available from a vendor, please provide details 
This probe molecule is available from Princeton BioMolecular Research, Inc. 
(Monmouth Jct, NJ) with a catalog number of OSSK_022127 (www.princetonbio.com) 
 
f. Provide MLS# that verifies the submission of probe molecule and related 
samples that were submitted to the SMR collection: 
 

















MLS002554749 0425632 85256223 6161281 PrincetonBio 50 10/16/09 
Analog1 MLS002554750 0425633 85256224 6274486 PrincetonBio 20 10/16/09 
Analog2 MLS002554751 0425634 85256225 5932584 PrincetonBio 20 10/16/09 
Analog3 MLS002554752 0425635 85256226 5998084 PrincetonBio 20 10/16/09 
Analog4 MLS002554753 0425636 85256227 6166563 PrincetonBio 20 10/16/09 
Analog5 MLS002554754 0425637 85256228 6001181 PrincetonBio 20 10/16/09 
 
g. Describe mode of action for biological activity of probe 
 
The resulting lead compound SID17460170 (1) competitively inhibited VHR with a Ki value 
of 0.81 uM and exhibited a promising degree of selectivity for VHR among other PTPs. In 
silico docking of SID17460170 (1) into the active site of VHR and SAR analysis suggested a 
binding mode, in which the sulfonic acid moiety of SID17460170 (1) binds through a 
network of hydrogen bond interactions into the phosphate binding pocket, whereas the 
thiazolidine heterocycle interacts with the rim of the pocket and the phenyl-allyl moiety 
makes van der Waals interactions with side chains of hydrophobic amino acids that flank the 
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active site. Besides highly improved potency 
against VHR with IC50 values as low as 18 nM, 
these multidentate inhibitors were at least 1 order 
of magnitude less potent for any other PTP tested, 
including HePTP and MKP-1, which share the same 
physiological substrate with VHR. This result 
provides a good example for a general applicable 
concept, in which targeting unique surface features 
outside of the catalytic pocket can generate 
selective small-molecule inhibitors for individual 
members of the PTP family.18 
 
The assay provider, Dr. Tautz found that VHR 
inhibitors are able to pass cell membrane barriers 
and target VHR in cultured cells.18 In particular, he 
tested the compounds in cervical cancer cells, 
which were shown earlier to express higher levels 
of endogenous VHR compared to noncancerous 
cells of the cervix. Indeed, incubation of the cancer 
cell line HeLa and CaSki with the inhibitors at 20 
uM induced a very significant inhibition of cell 
proliferation after an incubation period as short as 
24 h. 
 
It is interesting to note that  CID-5932584 (SA3) 
was more effective in inhibiting proliferation than  
CID-6161281 (SA1), although its IC50 value is four 
times higher in vitro. CID-5932584 (SA3) also 
exhibited greater antiproliferative effects than CID-
6274486 (SA2) and CID-5998084 (SA4), both of 
which share similar IC50 values with CID-5932584 
(SA3)  in vitro. 
These results suggest a beneficial role for the 
fluorine substituent (which is only present in CID-
5932584 (SA3), maybe by facilitating better 
membrane permeability. The latter could be a 
limiting factor for these compounds, considering 
the substantially higher concentration that is 
needed to see clear effects in cells vs. inhibition of 
recombinant protein. Nonetheless, the fact that 
these inhibitors are not toxic to cells with low levels 
of endogenous VHR, such as primary normal 
keratinocytes, these compounds may well be a 
starting point for development of drugs for the 
treatment of cervical cancer and perhaps other 
cancers. Indeed, our results provide first 
evidence that pharmacological inhibition of VHR 
could be beneficial in treating such diseases. 
However, additional studies will be necessary to 
get better insights into the role of VHR 
phosphatase in cell cycle regulation and cancer 
and to test the activity of these compounds in 




Figure 4. Effects of VHR inhibitors on proliferation and 
survival of cervix cancer cells. (A) Cell numbers of 
HeLa cervix carcinoma cells and normal keratinocytes 
(NK) after 24 h of treatment with 20 uM inhibitors, 
given as percentage of the DMSO control. (B,C) [3H]-
Thymidine incorporation assay with 20 uM inhibitors or 
vehicle (DMSO) in HeLa (B) or Caski (C) cervix cancer 
carcinoma cells. (D) Survival/death of HeLa and CasKi 
cells in presence of 20 uM inhibitors or DMSO after 24 
h, evaluated by Annexin V FITC/ PI flow cytometry 
assay (FACS Vantage, BD). Percentage of live cells 
(Annexin V negative and PI negative cells on flow 
cytometry dot plots) is given. All data are reported as 
mean ± SD from three independent experiments.  
(see ref. 18) 
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h. Detailed synthetic pathway for making probe 
Compound is obtained commercially, but BCCG did prepare a synthetic route. 
 
i. Center summary of probe properties (solubility, absorbance/fluorescence, 
reactivity, toxicity, etc.) 
This probe has demonstrated low micromolar potency for VHR and selectivity against HePTP 
and MKP-1.  In PubChem this compounds has been tested in only the SAR assays associated 
with the VHR project.  
 
While the probe compound CID6161281 [ML113] (MLS-0425632) contains a sulfonic acid 
that is expected to be fully negatively charged, however, it is also a very hydrophobic 
molecule.  Consistent with these characteristics, it exhibited low solubility and permeability 
at all pHs tested (Table 8).  It exhibits high plasma protein binding (both human and 
mouse). However, it has good stability in both human and mouse plasma. But, it has some 
instability in the presence of both human and mouse microsomes (determined by the 
exploratory pharmacology group).  The probe compound has a LD50 >50uM towards Fa2N-4 
immortalized human hepatocytes. 
 
 













































<0.8  (6.2) 










a in aqueous buffer, pH’s 5.0/6.2/7.4 
b  in aqueous buffer; Donor compartment pH’s 5.0/6.2/7.4; Acceptor compartment pH 7.4 
c % remaining at 3 hr 
d % remaining at 1 hr 
e towards Fa2N-4 immortalized human hepatocytes  
 
j. A tabular presentation summarizing known probe properties 
 
Table 9. Properties computed from Structure 
CID6161281  [ML113]  (MLS-0425632) 
Molecular Weight [g/mol] 612.13938 
Molecular formula C28H22ClN3O5S3 
XLogP3-AA 5.6 
H-Bond Donor 1 
H-Bond Acceptor 6 
Rotatable Bond Count 9 
Exact Mass 611.041011 
MonoIsotopic Mass 611.041011 
Topological Polar Surface Area 168 
Heavy Atom Count  40 
Formal Charge 0 
Complexity 1030 
Isotope Atom Count 0 
Defined Atom StereoCenter Count 0 
Undefined Atom StereoCenter Count 0 
Defined Bond StereoCenter Count 1 
Undefined Bond StereoCenter Count 0 
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Covalently-Bonded Unit Count 1 
 
4. Appendices (useful in a tabular form):  
a. Comparative data on (1) probe, (2) similar compound structures 
(establishing SAR) and (3) prior probes 
Already summarized above in Tables 1, 2, 5 and 6 
 
b. Comparative data showing probe specificity for target 
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